Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre, Open-label, Single-arm, Dose-finding Phase I/II Study to Evaluate Safety, Tolerability, Dosing Schedule, and Preliminary Efficacy of 131I-IPA, Administered in Patients With Recurrent GBM, Concomitantly With 2nd Line XRT

Trial Profile

A Multi-centre, Open-label, Single-arm, Dose-finding Phase I/II Study to Evaluate Safety, Tolerability, Dosing Schedule, and Preliminary Efficacy of 131I-IPA, Administered in Patients With Recurrent GBM, Concomitantly With 2nd Line XRT

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACD 101 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Acronyms IPAX-1
  • Sponsors Telix Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2019 Status changed from not yet recruiting to recruiting.
    • 25 Feb 2019 Planned initiation date changed from 11 Feb 2019 to 1 Mar 2019.
    • 23 Feb 2019 Status changed to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top